ArticleChemical & biomedical imaging2025
USSGAN: Unsupervised Spectral and Spatial Attention-Based Generative Adversarial Network for Cholangiocarcinoma Detection.
Article in Chemical & biomedical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma, a form of liver bile duct cancer, is challenging to detect due to its critically low 5-year survival rate. Conventional imaging modalities, such as Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), are widely used, but recent advancements in Hyperspectral Imaging (HSI) offer a promising, non-invasive alternative for cancer diagnosis. However, supervised learning methods often require large annotated datasets that can be difficult to obtain. To alleviate this limitation, we propose an unsupervised learning strategy using Generative Adversarial Networks (GANs) for cholangiocarcinoma detection. This approach, named Unsupervised Spectral and Spatial Attention-based GAN (USSGAN), employs an unsupervised Spectral-Spatial attention-based GAN to classify and segment cancerous regions without relying on labeled training data. The integration of an adaptive step size into Tasmanian Devil Optimization (TDO) enhances the convergence speed and effectively captures diverse cancerous features. Enhanced Tasmanian Devil Optimization (ETDO) further improves segmentation performance, making the framework robust and computationally efficient. The proposed method was tested on a publicly available multidimensional choledochal cholangiocarcinoma dataset, achieving superior performance compared with existing techniques in the literature. USSGAN demonstrated high accuracy across key metrics such as overall accuracy (OA), average accuracy (AA), and Cohen's Kappa. Ablation studies confirmed the critical contributions of the proposed enhancements to the overall performance. With an overall accuracy of 98.03%, the USSGAN closely aligns with the assessments of experienced pathologists while maintaining minimal computational requirements. Its lightweight nature ensures real-time deployment, providing results within a minute, making it a practical and effective solution for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.